
FDA Advisory Committee backs TRUQAP® (capivasertib) for PTEN-deficient metastatic hormone-sensitive prostate cancer
TRUQAP® (capivasertib)recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer The US Food and Drug Administration’s Oncologic Drugs Advisory Committee has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy…












